AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more
AstraZeneca PLC (AZN) - Total Assets
Latest total assets as of December 2025: $114.07 Billion USD
Based on the latest financial reports, AstraZeneca PLC (AZN) holds total assets worth $114.07 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AstraZeneca PLC - Total Assets Trend (1990–2025)
This chart illustrates how AstraZeneca PLC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AstraZeneca PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
AstraZeneca PLC's total assets of $114.07 Billion consist of 25.2% current assets and 74.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.0% |
| Accounts Receivable | $15.18 Billion | 13.3% |
| Inventory | $6.56 Billion | 5.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $37.85 Billion | 33.2% |
| Goodwill | $21.24 Billion | 18.6% |
Asset Composition Trend (1990–2025)
This chart illustrates how AstraZeneca PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AstraZeneca PLC's current assets represent 25.2% of total assets in 2025, a decrease from 58.1% in 1990.
- Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, up from 2.1% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 1990.
- Asset Diversification: The largest asset category is intangible assets at 33.2% of total assets.
AstraZeneca PLC Competitors by Total Assets
Key competitors of AstraZeneca PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198
|
China | CN¥774.73 Million |
|
PharmGen Science Inc
KO:004720
|
Korea | ₩331.46 Billion |
AstraZeneca PLC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - AstraZeneca PLC generates 0.51x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, AstraZeneca PLC generates $8.99 in net profit.
AstraZeneca PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.94 | 0.93 | 0.87 |
| Quick Ratio | 0.72 | 0.74 | 0.67 |
| Cash Ratio | 0.19 | 0.00 | 0.00 |
| Working Capital | $-1.89 Billion | $ -2.04 Billion | $ -2.78 Billion |
AstraZeneca PLC - Advanced Valuation Insights
This section examines the relationship between AstraZeneca PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.21 |
| Latest Market Cap to Assets Ratio | 2.59 |
| Asset Growth Rate (YoY) | 9.6% |
| Total Assets | $114.07 Billion |
| Market Capitalization | $295.24 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values AstraZeneca PLC's assets at a significant premium ( 2.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: AstraZeneca PLC's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AstraZeneca PLC (1990–2025)
The table below shows the annual total assets of AstraZeneca PLC from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $114.07 Billion | +9.65% |
| 2024-12-31 | $104.03 Billion | +2.88% |
| 2023-12-31 | $101.12 Billion | +4.80% |
| 2022-12-31 | $96.48 Billion | -8.43% |
| 2021-12-31 | $105.36 Billion | +57.90% |
| 2020-12-31 | $66.73 Billion | +8.72% |
| 2019-12-31 | $61.38 Billion | +1.20% |
| 2018-12-31 | $60.65 Billion | -4.27% |
| 2017-12-31 | $63.35 Billion | +1.32% |
| 2016-12-31 | $62.53 Billion | +4.00% |
| 2015-12-31 | $60.12 Billion | +2.61% |
| 2014-12-31 | $58.59 Billion | +4.82% |
| 2013-12-31 | $55.90 Billion | +4.42% |
| 2012-12-31 | $53.53 Billion | +1.33% |
| 2011-12-31 | $52.83 Billion | -5.87% |
| 2010-12-31 | $56.13 Billion | +2.20% |
| 2009-12-31 | $54.92 Billion | +16.98% |
| 2008-12-31 | $46.95 Billion | -2.10% |
| 2007-12-31 | $47.96 Billion | +60.22% |
| 2006-12-31 | $29.93 Billion | +20.50% |
| 2005-12-31 | $24.84 Billion | -3.17% |
| 2004-12-31 | $25.65 Billion | +8.82% |
| 2003-12-31 | $23.57 Billion | +9.26% |
| 2002-12-31 | $21.58 Billion | -18.41% |
| 2001-12-31 | $26.45 Billion | +43.36% |
| 2000-12-31 | $18.45 Billion | -6.87% |
| 1999-12-31 | $19.81 Billion | +120.56% |
| 1998-12-31 | $8.98 Billion | +8.43% |
| 1997-12-31 | $8.28 Billion | -3.28% |
| 1996-12-31 | $8.56 Billion | +8.80% |
| 1995-12-31 | $7.87 Billion | +7.54% |
| 1994-12-31 | $7.32 Billion | -1.43% |
| 1993-12-31 | $7.42 Billion | +19.97% |
| 1992-12-31 | $6.19 Billion | -2.73% |
| 1991-12-31 | $6.36 Billion | +4.27% |
| 1990-12-31 | $6.10 Billion | -- |